UK 279276Alternative Names: Corleukin NIF; Recombinant neutrophil inhibitory factor; rNIF
Latest Information Update: 27 Jun 2002
At a glance
- Originator Dendreon San Diego LLC
- Class Neuroprotectants
- Mechanism of Action CD11b antigen antagonists; CD18 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke